GMAB logo

Genmab A/S (GMAB)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Genmab A/S (GMAB) ist im Healthcare-Sektor taetig, zuletzt notiert bei $26.03 mit einer Marktkapitalisierung von 17B. Die Aktie erzielt 58/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 15. März 2026
58/100 KI-Bewertung Ziel $40.17 (+54.3%) MCap 17B Vol 4M

Genmab A/S (GMAB) Gesundheitswesen & Pipeline-Uebersicht

CEOJan van de Winkel
Mitarbeiter2638
HauptsitzCopenhagen, DK
IPO-Jahr2009

Genmab A/S, a Danish biotechnology firm, focuses on developing innovative antibody therapeutics for cancer and other diseases, marketing key products like DARZALEX and teprotumumab. With a robust pipeline and strategic collaborations, Genmab aims to address unmet medical needs in oncology and immunology, holding a strong position in the antibody therapeutics market.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 15. März 2026

Investmentthese

Genmab A/S presents a compelling investment case driven by its robust pipeline of antibody therapeutics and strategic partnerships. The company's marketed products, including DARZALEX and teprotumumab, generate substantial revenue, reflected in a profit margin of 16.7% and a gross margin of 93.6%. Key growth catalysts include the advancement of its Phase 2 clinical programs and potential regulatory approvals for novel therapies. The company's collaboration agreements with industry leaders like AbbVie and Janssen further de-risk its development pipeline. However, potential risks include clinical trial failures and increased competition in the biotechnology sector. With a market capitalization of $16.11 billion and a P/E ratio of 25.88, Genmab's valuation reflects its growth potential and established market presence.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $16.11 billion, indicating a strong market valuation.
  • P/E ratio of 25.88, reflecting investor expectations for future earnings growth.
  • Profit margin of 16.7%, demonstrating efficient operations and profitability.
  • Gross margin of 93.6%, showcasing the high value of its therapeutic products.
  • Beta of 0.75, suggesting lower volatility compared to the overall market.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Strong portfolio of marketed products, including DARZALEX and teprotumumab.
  • Robust pipeline of antibody therapeutics in clinical development.
  • Strategic collaborations with leading pharmaceutical companies.
  • High gross margin of 93.6%.

Schwaechen

  • Reliance on a limited number of key products for revenue generation.
  • High research and development expenses.
  • Potential for clinical trial failures.
  • Exposure to regulatory risks.

Katalysatoren

  • Upcoming: Regulatory approval decisions for Teclistamab in relapsed/refractory multiple myeloma.
  • Upcoming: Data readouts from Phase 2 clinical trials for Camidanlumab tesirine in Hodgkin lymphoma and solid tumors.
  • Ongoing: Expansion of DARZALEX into new indications, including non-MM blood cancers and AL amyloidosis.
  • Ongoing: Strategic collaborations with pharmaceutical companies to develop and commercialize new antibody therapeutics.

Risiken

  • Potential: Clinical trial failures for key pipeline candidates.
  • Potential: Increased competition in the antibody therapeutics market.
  • Potential: Patent expirations for key products.
  • Ongoing: Regulatory risks associated with drug development and commercialization.
  • Ongoing: Currency risk due to fluctuations in the exchange rate between the U.S. dollar and the Danish Krone.

Wachstumschancen

  • Expansion of DARZALEX into New Indications: DARZALEX, Genmab's flagship product for multiple myeloma, has the potential for expansion into new indications, including non-MM blood cancers and AL amyloidosis. This expansion could significantly increase revenue streams and market share. The market for multiple myeloma therapeutics is projected to reach $37.5 billion by 2030, providing a substantial growth opportunity for Genmab.
  • Advancement of Phase 2 Clinical Programs: Genmab has several promising products in Phase 2 clinical trials, including Teclistamab, Camidanlumab tesirine, and Mim8. Successful completion of these trials and subsequent regulatory approvals could lead to the launch of new blockbuster drugs. The timeline for these approvals is estimated to be within the next 3-5 years, offering a near-term growth catalyst.
  • Strategic Collaborations and Partnerships: Genmab's collaboration agreements with industry leaders like AbbVie, Janssen, and BioNTech provide access to cutting-edge technologies and resources. These partnerships de-risk the development pipeline and accelerate the commercialization of new therapies. The value of these collaborations is estimated to be in the billions of dollars, offering a significant boost to Genmab's long-term growth prospects.
  • Geographic Expansion into Emerging Markets: Genmab has the opportunity to expand its geographic presence into emerging markets, particularly in Asia and Latin America. These markets offer significant growth potential due to increasing healthcare spending and a growing prevalence of cancer and autoimmune diseases. The timeline for this expansion is estimated to be within the next 5-10 years.
  • Development of Next-Generation Antibody Therapeutics: Genmab is actively engaged in the development of next-generation antibody therapeutics, including bispecific antibodies and antibody-drug conjugates. These innovative therapies have the potential to revolutionize the treatment of cancer and other diseases. The market for bispecific antibodies is projected to reach $12.4 billion by 2028, providing a substantial growth opportunity for Genmab.

Chancen

  • Expansion into new therapeutic areas.
  • Geographic expansion into emerging markets.
  • Development of next-generation antibody therapeutics.
  • Acquisition of complementary technologies or companies.

Risiken

  • Competition from other biotechnology and pharmaceutical companies.
  • Patent expirations.
  • Pricing pressures.
  • Changes in healthcare regulations.

Wettbewerbsvorteile

  • Proprietary antibody technology platforms.
  • Strong intellectual property protection.
  • Established partnerships with leading pharmaceutical companies.
  • Deep expertise in antibody therapeutics development.

Ueber GMAB

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab A/S is a biotechnology company dedicated to creating and developing differentiated antibody therapeutics for the treatment of cancer and other diseases. The company's evolution has been marked by strategic collaborations and a focus on innovative research and development. Genmab markets DARZALEX, a human monoclonal antibody for multiple myeloma (MM), teprotumumab for thyroid eye disease, ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its diverse product portfolio includes daratumumab for MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for hematological malignancies. Genmab also has approximately 20 active pre-clinical programs and several products in Phase 2 clinical trials, including Teclistamab, Camidanlumab tesirine, JNJ-64007957, JNJ-64407564, PRV-015, Mim8, and Lu AF82422. The company has established collaborations with CureVac AG, AbbVie, BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc., enhancing its research and development capabilities. Genmab's commitment to innovation and strategic partnerships positions it as a key player in the antibody therapeutics market.

Was das Unternehmen tut

  • Develops antibody therapeutics for cancer and other diseases.
  • Markets DARZALEX for the treatment of multiple myeloma (MM).
  • Markets teprotumumab for the treatment of thyroid eye disease.
  • Develops ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis.
  • Develops Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
  • Conducts Phase 2 clinical trials for various therapeutic candidates.
  • Engages in pre-clinical research and development programs.

Geschaeftsmodell

  • Develops and commercializes antibody therapeutics.
  • Generates revenue through product sales and royalties.
  • Collaborates with other pharmaceutical companies for research and development.
  • Out-licenses its technologies and products to partners.

Branchenkontext

Genmab A/S operates within the biotechnology industry, a sector characterized by rapid innovation and intense competition. The market for antibody therapeutics is experiencing substantial growth, driven by the increasing prevalence of cancer and autoimmune diseases. Key competitors include companies like DGX, EXEL, ILMN, INCY, and ROIV, each vying for market share with their own unique therapeutic approaches. Genmab distinguishes itself through its focus on differentiated antibody therapeutics and strategic collaborations, positioning it to capitalize on the growing demand for innovative treatments.

Wichtige Kunden

  • Patients with cancer and other diseases.
  • Hospitals and clinics.
  • Pharmaceutical companies.
  • Healthcare providers.
KI-Zuversicht: 73% Aktualisiert: 15. März 2026

Finanzdaten

Chart & Info

Genmab A/S (GMAB) Aktienkurs: $26.03 (-0.08, -0.31%)

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GMAB.

Kursziele

Konsens-Kursziel: $40.17

MoonshotScore

58/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von GMAB auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Klassifizierung

Sektor Healthcare Branche Biotechnology

Wettbewerber & Vergleichsunternehmen

Aktuelle Nachrichten

Neueste Genmab A/S-Analyse

Fuehrung: Jan van de Winkel

Chief Executive Officer

Jan van de Winkel has served as the Chief Executive Officer of Genmab A/S, managing a workforce of 2638 employees. His career spans over two decades in the biotechnology and pharmaceutical industries. He holds a Ph.D. in Immunology from the University of Nijmegen and has authored numerous scientific publications. Prior to joining Genmab, he held leadership positions at various biotech companies, focusing on antibody therapeutics and drug development. His expertise lies in translating scientific discoveries into innovative treatments for cancer and other diseases.

Erfolgsbilanz: Under Jan van de Winkel's leadership, Genmab has achieved significant milestones, including the successful development and commercialization of DARZALEX and teprotumumab. He has overseen the expansion of Genmab's pipeline through strategic collaborations and acquisitions. His tenure has been marked by a focus on innovation and a commitment to developing differentiated antibody therapeutics. The company's market capitalization has grown substantially under his leadership, reflecting his strategic vision and execution.

Genmab A/S ADR-Informationen Gesponsert

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. GMAB, as an ADR, allows U.S. investors to invest in Genmab A/S without the complexities of cross-border transactions. Each GMAB ADR represents a specific number of Genmab A/S shares traded on its home market, simplifying ownership and trading for U.S. investors.

  • Heimatmarkt-Ticker: Nasdaq Copenhagen, Denmark
  • ADR-Stufe: 2
  • ADR-Verhaeltnis: 1:1
Waehrungsrisiko: Investing in GMAB as an ADR exposes U.S. investors to currency risk. The value of the ADR can be affected by fluctuations in the exchange rate between the U.S. dollar and the Danish Krone. If the Krone weakens against the dollar, the value of the ADR may decrease, even if the underlying Genmab A/S shares perform well in their home market.
Steuerliche Auswirkungen: U.S. investors in GMAB ADRs may be subject to foreign dividend withholding tax by the Danish government. The standard withholding tax rate is typically 27%. However, the U.S. has a tax treaty with Denmark that may reduce this rate for eligible investors. It's important to consult a tax advisor for personalized advice.
Handelszeiten: The Nasdaq Copenhagen typically operates from 09:00 to 17:00 Central European Time (CET). This translates to 03:00 to 11:00 Eastern Time (ET). Therefore, there is a significant overlap with U.S. trading hours, allowing investors to trade GMAB ADRs during regular market hours, though early morning trading may see lower liquidity.

Was Anleger ueber Genmab A/S (GMAB) wissen wollen

What are the key factors to evaluate for GMAB?

Genmab A/S (GMAB) currently holds an AI score of 58/100, indicating moderate score. The stock trades at a P/E of 25.4x, near the S&P 500 average (~20-25x). Analysts target $40.17 (+54% from $26.03). Key strength: Strong portfolio of marketed products, including DARZALEX and teprotumumab.. Primary risk to monitor: Potential: Clinical trial failures for key pipeline candidates.. This is not financial advice.

How frequently does GMAB data refresh on this page?

GMAB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven GMAB's recent stock price performance?

Recent price movement in Genmab A/S (GMAB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $40.17 implies 54% upside from here. Notable catalyst: Strong portfolio of marketed products, including DARZALEX and teprotumumab.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider GMAB overvalued or undervalued right now?

Determining whether Genmab A/S (GMAB) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 25.4. Analysts target $40.17 (+54% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying GMAB?

Before investing in Genmab A/S (GMAB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding GMAB to a portfolio?

Potential reasons to consider Genmab A/S (GMAB) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong portfolio of marketed products, including DARZALEX and teprotumumab.. Additionally: Robust pipeline of antibody therapeutics in clinical development.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of GMAB?

Yes, most major brokerages offer fractional shares of Genmab A/S (GMAB) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track GMAB's earnings and financial reports?

Genmab A/S (GMAB) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GMAB earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Information is based on publicly available sources and may be subject to change.
  • Financial data is as of 2026-03-15.
Datenquellen

Popular Stocks